AI Article Synopsis
Article Abstract
Background: Congenital infection with cytomegalovirus (CMV) is an important cause of hearing, cognitive, and motor impairments in newborns.
Methods: In this phase 2, placebo-controlled, randomized, double-blind trial, we evaluated a vaccine consisting of recombinant CMV envelope glycoprotein B with MF59 adjuvant, as compared with placebo. Three doses of the CMV vaccine or placebo were given at 0, 1, and 6 months to CMV-seronegative women within 1 year after they had given birth. We tested for CMV infection in the women in quarterly tests during a 42-month period, using an assay for IgG antibodies against CMV proteins other than glycoprotein B. Infection was confirmed by virus culture or immunoblotting. The primary end point was the time until the detection of CMV infection.
Results: We randomly assigned 234 subjects to receive the CMV vaccine and 230 subjects to receive placebo. A scheduled interim analysis led to a stopping recommendation because of vaccine efficacy. After a minimum of 1 year of follow-up, there were 49 confirmed infections, 18 in the vaccine group and 31 in the placebo group. Kaplan-Meier analysis showed that the vaccine group was more likely to remain uninfected during a 42-month period than the placebo group (P=0.02). Vaccine efficacy was 50% (95% confidence interval, 7 to 73) on the basis of infection rates per 100 person-years. One congenital infection among infants of the subjects occurred in the vaccine group, and three infections occurred in the placebo group. There were more local reactions (pain, erythema, induration, and warmth) and systemic reactions (chills, arthralgias, and myalgias) in the vaccine group than in the placebo group.
Conclusions: CMV glycoprotein B vaccine has the potential to decrease incident cases of maternal and congenital CMV infection. (ClinicalTrials.gov number, NCT00125502.)
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753425 | PMC |
| http://dx.doi.org/10.1056/NEJMoa0804749 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Proteomic analysis of the subsp. SS14 strain: coverage and comparison with the Nichols strain proteome.
Front Microbiol
December 2024
Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
Introduction: Strains of the syphilis spirochete, ssp. , group into one of two deep-branching clades: the Nichols clade or the globally dominant Street Strain 14 (SS14) clade. To date, in-depth proteome-wide analyses have focused on Nichols clade strains.
View Article and Find Full Text PDFMolecular characterization and antimicrobial susceptibility for 62 isolates of from children.
Front Microbiol
December 2024
Hebei Key Laboratory of Pathogens and Epidemiology of Infectious Diseases, HeBei Provincial Center for Disease Control and Prevention, Shijiazhuang, China.
Background: Pertussis is a highly contagious respiratory disease caused by (BP). Despite global control of pertussis cases through the Expanded Programme on Immunization (EPI), there has been a significant increase in the incidence of pertussis in recent years, characterized by a "resurgence" in developed countries with high immunization rates as well as a comparable reemergence in certain areas of China. We aim to explore the genotypes and antimicrobial susceptibility of circulating BP from children in Hebei.
View Article and Find Full Text PDFAcceptance of COVID-19 vaccine and its related determinants in Nigeria: An online survey.
World J Virol
December 2024
Department of Medical Laboratory Science, School of Public and Allied Health, Babcock University, Ilishan-Remo, OG 121109, Nigeria.
Background: Vaccine hesitancy is a major challenge in the fight against the coronavirus disease 2019 (COVID-19) pandemic. Identifying the sociodemographic factors associated with vaccine acceptance among Nigerians is crucial for improving vaccine uptake.
Aim: To assess the acceptance rate of COVID-19 vaccine and its related determinants among Nigerians.
Rift Valley Fever outbreaks in the East African Community: insights from ProMed data (2010-2024).
Front Public Health
December 2024
Stansile Research Organization, Kigali, Rwanda.
Background: Rift Valley Fever (RVF) is a mosquito-borne zoonotic disease that poses a serious threat to both humans and livestock across various regions, particularly in Africa, the Arabian Peninsula, and parts of the Indian Ocean Islands. This study seeks to analyze the spatial and temporal distribution and trends of RVF outbreaks within the East African Community (EAC) countries, offering insights into the patterns and progression of these outbreaks in the region.
Methods: We conducted a retrospective analysis of the Program for Monitoring Emerging Diseases (ProMed), a digital, event-based disease surveillance system, to identify reports of outbreak events in Uganda, Kenya, Rwanda, Burundi, Tanzania, and South Sudan from 2010 to 2024.
Background: A MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the five meningococcal serogroups that cause most invasive disease cases.
Methods: In this phase 3 study (NCT04707391), healthy participants aged 15-25 years, who had received MenACWY vaccination ≥4 years previously, were randomized (1:1) to receive two MenABCWY doses six months apart or one MenACWY-CRM dose. Primary objectives were to demonstrate the non-inferiority of MenABCWY 1 month post-vaccination versus MenACWY-CRM, with a lower limit of 2-sided 95% confidence interval above -10% for group differences in 4-fold rise in human serum bactericidal antibody (hSBA) titers against serogroups ACWY, and to evaluate reactogenicity and safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!